WO1996014308A1 - Taxane derivatives - Google Patents

Abstract

Taxane derivatives modified at 13-position of the taxane derivative skeleton (taxol numbering) of formula (I), wherein R, Ra, Rb, Rc, R1, R2, R3 are appropriate organic residues can be antitumour agents.

Description

TAXANE DERIVATIVES

The present invention is directed to new taxane derivatives

endowed with antitumour activity, to a process for their

preparation and to pharmaceutical compositions containing them.

The taxane family of diterpenes includes Paclitaxel (also

named taxol in several publications) , isolated and

characterized from an extract of bark of Taxus brevifolia L., and Cephalomannine (see J.Chem.Soc. Chem. Comm.102, 1979);

other taxane analogues are also known and were prepared by

semisynthesis starting from lO-deacetyl baccatin III, extracted from the needles of Taxus baccata L. (see Wani et

al. , J.Am.Chem.Soc.93, 2325, 1971; Lovelle et al., Proc.Am.Assoc.Cancer Res.31, 417, 1990) .

Particularly, paclitaxel is a very potent anticancer drug and

is already applied with success to the treatment of

platinum-resistant ovarian cancer. Nevertheless there is a continuous need for more potent compounds having the broadest

possible spectrum of activity on different cancer types.

The present invention provides taxane derivatives modified

at the 13-position of the taxane skeleton (taxol numbering) .

More especially, the invention provides taxane derivatives of

the formula I:

wherein: R represents a hydrogen atom or a hydroxy group, or taken together with R₃, a bond;

(i) R_a and R_c are hydrogens and R is hydroxy, or (ii) R_a and R_b taken together form a bond and R_c is hydrogen, or

(iii) R_a is hydrogen atom and R_b and R_c taken together form

a bond, or R_b is azido or amino group and R_c is hydrogen atom;

R_x represents a hydrogen atom, a hydroxy group or a residue

of formula -0C0R¹ , -OR', -0S0₂R* , -OCONR'R", -0C0NHR' or -0C00R' wherein R' and R" are each independently Ci-Cg alkyl,

preferably methyl, phenyl-C₂-C₆ alkenyl or phenyl-C₂-C₆ alkyl,

C₃-C₆ cycloalkyl, C₂-C₆ alkynyl or a phenyl group, optionally

substituted with one, two or three substituents which may be

the same or different and which are selected from a halogen

atom and C₁-C₆ alkyl,

alkoxy and -CF₃ groups; and

either

(i) R₂ and R₃ together represent a group of the formula A-

N=, as pure E or pure Z isomers or as a mixture of both E and

Z isomers, wherein A represents:

- a hydrogen atom or a hydroxy, methoxy, acetoxy, amino,

methylamino or dimethylamino group, or

- a group of the formula Y-NH- wherein Y represents either

(a) residue of an amino acid, preferably glycine,

phenylglycine, serine, 3-phenylserine, β-alanine and the

like, optionally protected at the amino group as a N-

benzoyl derivative or as a carbamate, or

(b) a chain of the formula II:

wherein:

R₄ is a Ci-Cg alkyl, C₂-C₆ alkenyl, C₃-C₆ cycloalkyl group or a phenyl or heteroaryl group, optionally substituted with one,

two or three substituents which may be the same or different

and which are selected from a halogen atom and Ci-C₆ alkyl, Ci-

Cg alkoxy, or -CF₃ groups,- and

R₅ is -COOR' ' ' or -COR' ' ' , or CONHR' ' ' wherein R' ' ' is Ci-

Cg alkyl, preferably tert-butyl or n-pentyl, C₂-C₆ alkenyl, preferably 1-methyl-l-propenyl, C₃-C₆ cycloalkyl, C₂-C₆ alkynyl

or a phenyl group, optionally substituted with one, two or

three substituents which may be the same or different and which are selected from a halogen atom and C_ι-C₆ alkyl, Ci-C₆

alkoxy and -CF₃ groups,- or a group of the formula Y or Y-O- wherein Y is as defined above,-

a group of the formula COR' wherein R' is as defined above,-

or

(ii) R₂ represents a group of the formula B-NH- wherein B

represents

a) hydrogen atom,

b) hydroxy group, c) amino group,

d) a group of the formula Y-(NH)_n- wherein Y is as defined

above and n is 0 or l, or

e) a group of the formula Y-O- wherein Y is as defined above,-

f) a group of the formula COR' wherein R' is as defined above,-

and R₃ represents hydrogen, or, taken with R , a bond;

and pharmaceutically acceptable salts thereof.

The R₂ substituent may be in the R or S configuration.

Alternatively the R₂ substituent may be in both the R and S

configurations i.e. a mixture of stereoisomers is present.

A Ci-Cg alkyl group is a straight or branched alkyl group,

preferably a Ci-C₄ alkyl group such as methyl, ethyl, n-propyl,

isopropyl, n-butyl, isobutyl, sec-butyl, ter -butyl or n-

pentyl . A C₂-C₆ alkenyl group is a straight or branched

alkenyl group, preferably a C₂-C₅ alkenyl group such as vinyl,

allyl, crotyl, 2-methyl-1-propenyl, 1-methyl-l-propenyl,

butenyl or pentenyl . A C₃-C₆ cycloalkyl group is a saturated

carbocyclic group of 3 to 6 carbon atoms, such as cyclopropyl,

cyclobutyl, cyclopentyl or cyclohexyl .

A halogen is preferably fluorine, chlorine, bromine or

iodine. The heteroaryl group is preferably a 3- to 6-membered,

saturated or unsaturated heterocyclyl ring which contains at

least one, for example 1, 2 or 3, heteroatoms selected from 0,

S and N and which is optionally fused to a second 5- or 6-

membered, saturated or unsaturated heterocyclyl group

containing 1 or more, for example, 1, 2, or 3 hetereoatoms or

to a cycloalkyl group or to an aryl group. The 3- to 6-

membered heterocycyl ring may be a 3-, 4-, 5- or 6- membered such ring. A cycloalkyl group is generally a said C₃-C₆ cycloalkyl group. An aryl group is generally phenyl or

naphthyl.

Examples of heterocyclyl groups are pyrrolyl, pyrazolyl,

imidazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, thiadiazolyl,thienyl, furyl,

aziridinyl, oxiranyl, azetidinyl, pyridinyl, pyrazinyl,

pyrimidinyl, pyranyl, pyridazinyl, benzothienyl,

benzothiazolyl, benzoxazolyl, isobenzofuranyl, benzofuranyl,

chromenyl, indolyl, indolizinyl, isoindolyl, cinnolinyl,

indazolyl and purinyl.

A C₂-C₆ alkenediyl chain can be a straight or branched

alkenediyl preferably a C₂-C₄ alkenediyl chain such as -CH=CH-, -CH=CH-CH₂- or -CH(CH₃) -CH=CH- . The C₂-C₆ alkynyl group is a

straight or branched alkynyl group preferably a C₂-C₄ alkynyl

chain such as ethynyl, propargyl, 1-propynyl, 1-butynyl or 2-

butynyl. A C_ι-C₆ alkoxy group can be a straight chain or

branched alkoxy group, preferably a C_ι~C₄ alkoxy group such as

methoxy, ethoxy, n-propoxy, n-butoxy or tert-butoxy.

Preferred compounds of the invention are taxane derivatives

of formula I, wherein:

R_a and R_c are hydrogen atoms and R_b is hydroxy, R_x

represents a hydrogen atom, a hydroxy group or a residue of

formula -OCOR' , -OR', -0S0₂R' , -OCONR'R", -OCONHR' or -OCOOR'

wherein R' and R" are each independently C_ι-C₄ alkyl, C₂-C₃ alkenyl, C₃-C₆ cycloalkyl, C₂-C₅ alkynyl or a phenyl group,

optionally substituted with one, two or three substituents

which may be the same or different and which are selected from a halogen atom and C_ι-C₄ alkyl, C_ι~C₄ alkoxy and -CF₃ groups,-

and either:

(i) R₂ and R₃ together represent a group of the formula A-N=,

as pure E or pure Z isomers or as a mixture of both E and Z

isomers, wherein A represents: - a hydrogen atom, a hydroxy, methoxy, acetoxy, amino,

methylamino or dimethylamino groups, or

- a group of the formula Y-NH- wherein Y represents either

(a) residue of an amino acid optionally protected at the

amino group as a N-benzoyl derivative or as a carbamate,

or

(b) a chain of the formula II:

wherein:

R₄ is a Ci-C- alkyl, C₂-C₅ alkenyl, C₃-C₆ cycloalkyl group or a

phenyl or heteroaryl group, optionally substituted with one,

two or three substituents which may be the same or different

and which are selected from a halogen atom and C_ι-C₄ alkyl, Ci-

C₄ alkoxy and -CF₃ groups;

R₅ is -COOR' ' ' or -COR' ' ' or -CONHR' ' ' wherein R' " is Ci~C₄

alkyl, C₂-C₅ alkenyl, C₃-C₆ cycloalkyl, C₂-C₄ alkynyl or a

phenyl group, optionally substituted with one, two or three

substituents which may be the same or different and which are selected from a halogen atom and Cι~C₄ alkyl, Cι~C₄ alkoxy and

-CF₃ groups; or

a group of the formula Y or Y-0- wherein Y is as defined

above; or

(ii) R₂ represents a group of the formula -NH-B wherein B

represents

a) hydrogen atom,

b) hydroxy group,

c) amino group,

d) a group of the formula Y-(NH)_n- wherein Y is as defined

above and n is 0 or 1, or

e) a group of the formula Y-0- wherein Y is as defined above;

f) a group of the formula COR' wherein R' is as defined above,

and R₃ represents hydrogen, taken together with R, a bond.

Ri is preferably a hydrogen atom, a hydroxy group or an acetoxy

group; R₃ is preferably a hydrogen atom. R₂ preferably

represents the group of formula NHB. B is preferably the

chain of formula II.

R₄ is preferably phenyl or 2-furyl. R₅ is benzoyl or t- butoxycarbonyl group.

The pharmaceutically acceptable salts are typically those salts formed with pharmaceutically acceptable acids, both inorganic acids like hydrochloric, hydrobromic, sulfuric, phosphoric, diphosphoric, or nitric acid and organic acids such as citric, fumaric, maleic, malic, ascorbic, succinic, tartaric, benzoic, acetic, methanesulphonic, ethanesulfonic, benzenesulfonic or p-toluenesulfonic acid.

Further preferred compounds of the invention are: 13-aza-paclitaxel, 13-aza-10-desacetoxy paclitaxel, 13-aza-10- desacetyl paclitaxel, 13-aza-taxotere, l3-aza-10-deoxy- taxotere, 10 deacetoxy-13-deoxy-13-imino paclitaxel, 10,13 dideoxy-13-imino taxotere, 13-deoxy-13-imino paclitaxel, 13- deoxy-13-imino taxotere, 10-deacetoxy-13-deoxy-13, 14 ene-13- aza-paclitaxel, 13-deoxy-13, 14 ene-13-aza-paclitaxel, 10,13- dideoxy-13, 14 ene-13 aza-taxotere, 13,14 ene-13-aza-taxotere. The suffix "aza" means that the oxygen atom of the substituent at position 13 of the taxol structure has been replaced with an NH residue.

The present invention also provides a process for the preparation of taxane derivatives of formula I as above defined. The following scheme illustrates the reaction sequence:

IVC + IV

(IV, IVa, IVb.IVc- VII or VII I or IX) +(Xa,Xb, Xc or Xd or

Aminoacid) -> XI (e)

IV, IVa, IVb,IVc,IVd V, VI, VII, VIII or IX or XI deprotection or reduction when necessary _τ

(f)

The process comprises, in a first step (a) , the reaction of

a 7-protected-13-keto-baccatin derivative of the formula III

wherein R_1# R_a and R_c are as defined above and R'_b or has the same meanings of R_b except for OH or NH₂, either represents a

protected amino or hydroxy group, in which the protecting

group is trialkylsilyl or other hydroxy protecting groups such as phenyldimethylsilyl, triisopropylsilyl, t-

butyldimethylsilyl, dimethyl- (1-methyl, 2-methyl)propylsilyl, t-

butyldiphenylsilyl, acetyl, benzyloxycarbonyl, 2,2,2-

trichloroethoxycarbonyl and the like, with hydroxylamine, 0-

methylhydroxylamine, methyl-hydrazine, N,N-dimethylhydrazine,

or with ammonia or an ammonium salt such as ammonium chloride,

bromide or formate and optionally acylating the resulting

compound thereby to give a compound of formula IV, IVb, IVd, V

or VI, obtained as pure E or pure Z or as a mixture of E and Z

isomers. Typically the reaction involving the 7-protected-13- keto-baccatin derivative is carried out in a solvent such as

pyridine at temperatures ranging from room temperature to the

boiling point of the solvent. The optional acylation of the

intermediate of formula IVb may be carried out with a

conventional acylating agent, such as acetic anhydride or

benzoyl chloride to give a compound IVd.

It is to be noted that the compound of the formula IVd may

exist also as a tautomer of formula IVd

that is R₃ and R taken together are a bond, which can be

partially reduced and deprotected to give the derivative of

the formula IX as defined above. In a second step (b) , the 13-hydrazones of formula VI may

be reacted with anhydrous hydrazine to give a taxane

derivative of formula VII, which is then optionally reduced to

a hydrazine derivative of formula VIII using standard procedures

(e.g. reduction with catalytical hydrogenation such as in the

presence of Raney Ni, Pt or Pd) . In step (c) , the resultant 13-oxime of formula IV may be

partially reduced, e.g. with boranes, borohydrides or with

catalytical hydrogenation such as in the presence of Raney

Nickel, Pt or Pd, to give the hydroxylamino derivatives of the

formula IVa or the imino derivatives of the formula IVb.

In this step, when the reduction is carried out in the

presence of Ni/Raney and hydrazine, there are obtained also derivatives of the formula IVb wherein Ri represents hydrogen

atom. The compound of formula IVb may be oxidized in the

presence of organic peracid, such as m-chloro perbenzoic acid

to give again a compound of the formula IV and the derivative

of formula IVc having R=OH.

In step (d) , the compound of formula IV, IVa, ,- IVc, V or

VI can optionally be reduced to give the amino derivative of formula IX using standard procedures (e.g. reduction with

borohydrides or by catalytic hydrogenation) .

In step (e) , the C-13 derivatives of formula IV, IVa, IVb, VII, VIII or IX can be acylated with an appropriately

protected amino acid (the hydroxy group, if present, will be

conveniently protected, for example as 0- (l-ethoxyethyl)ether

or as -triethylsilyloxy) or with a molecule of the formula Xa

or Xb, Xc or Xd, optionally conveniently activated at the carboxy group

Xa Xb Xc Xd

wherein R_A is a hydroxy protecting group, preferably wherein R_A is a hydroxy protecting group, preferably

l-ethoxyethyl, triethylsilyl, t-butyldimethylsilyl, R_B is H or CH₃, R_c is CH₃ or an optionally substituted phenyl group,

preferably 2,4 dimethoxy or 4 methoxy phenyl group, R_D is an

optionally substituted phenyl group as for R_c and R₄ and R₅ are as defined above, in the presence of a condensing agent such

as -dicyclohexylcarbodiimide (DCC) or di-2-pyridylcarbonate

(DPC) , in toluene and 4-dimethylaminopyridine (DMAP) or

- sodium hexamethyldisilazide (NaHMDS) in tetrahydrofurane

(THF) to give the protected intermediate of the formula XI.

The useful intermediate derivatives of the formulas IV, IVa, IVb, IVc, IVd, IVd, V, VI, VII VIII, IX and XI are

also novel and are within the scope of the invention. In the final optional step (f) , the compounds of the

formula IV, IVa, IVb, IVc, IVd, V, VI, VII, VII, IX and XI are then deprotected and if wanted reduced, when R_b' is azido

group, to give the said taxane derivative of the formula I. In

this final step, when R_b' is a protected amino or hydroxy

group, the deprotection is carried out for example by

treatment with (n-Bu)₄NF, HF/Pyridine, HF/MeCN, Zn/AcOH. When

the acylating groups employed^' in step (e) were protected, the protecting groups are conveniently removed by appropriate

methods, in the last step (f) , for example when the acylating

molecula of formula X_c, as above defined, is used, the

protecting group is removed in acidic conditions, such as with

HCl/MeOH or EtOH, HCOOH 99%, CF₃C0₂H organic solvent (CH₂C1₂) .

The resultant compounds of the formula I may also be converted

into different compounds of the formula I by appropriate known

reactions, after necessary protections, for example the

compounds of formula I wherein R_a=R_c=H, and R_b is OH, may be

converted into a compound of formula I wherein R_a and R_b taken

together form a bond by protection of the hydroxy group,

reaction with triflic anhydride and treatment with a base. The

preparation of the starting compounds of the formula III, Xa,

Xb, Xc and Xd are known or may be carried out according to known methods; for example 7-triethylsilyl-3-keto-baccatin

(III, R=triethylsilyl, Ri=0C0CH₃) has already been described

[see J.Chem.Soc, Chem.Commun. , (1994), 295, Chem. Comm.

(1970), 216 , J.A.C.S. , (1971) ,91, 2325, Tetrahedron Asymmetry

1992, 2, 1007, JOC 1991, 56_, 1681, Tetrahedron 1992,48., 6985,

Tetrahedron Letters 1992, H, 5185, JOC 1993, 5_£, 1287, EP-A

400971, 1990.] In a further aspect, the present invention also provides a

compound of formula la

wherein R_a, R_b, R_c and R_x are as above defined, R₇ is hydrogen

atom or an acyl residue of formula COR' or Y, wherein Y and R' are defined above and the pharmaceutically acceptable salt

thereof.

The compound of formula la and the pharmaceutically acceptable salt thereof may be prepared by a process which comprises:

(a) reducing a compound of the formula IVb as above defined, optionally in the presence of an acylating agent, to give a

compound of formula XII

wherein R_1; R_a, R_b' , R_c and R₇, are as above defined except

that R₇ is not a hydrogen atom, b) deprotecting the resultant compound of the formula XII to

give a compound of formula la and c) optionally salifying the thus obtained compound of formula

la to give a pharmaceutically acceptable salt thereof.

Step (a) may be effected by using standard conditions such as

reduction with a borohydride such as sodium cyanoborohydride

or catalytic hydrogenation.

Step (b) can be carried out as described above for step (f)

The appropriate acylating agent may be selected from the group

of activated/protected carboxylic acid derivatives, such as

acetic anhydride, benzoyl chloride, cinnamoyl chloride,

isobutanoylchloride and the like.

BIOLOGICAL ACTIVITY

The cytotoxic activity of the compounds may be evaluated on

B₁₆-F₁₀ murine melanoma cell line which was responsive to

paclitaxel . The mode of action of the compound may also be

tested on the tubulin assembly-disassembly assay in comparison

with taxol a reference compound.

(A) In vitro druσ sensitivity assay.

Exponentially growing B₁₆-F₁₀ murine melanoma cells were

seeded (2xl0⁴/ml) in RPMI 1640 medium supplemented with 10%

heat-inactivated fetal calf serum and 2mM glutamine in 24-well

plates (Costar) . Scaled concentrations of tested compounds

were added immediately after seeding. The inhibition of cell

growth was evaluated by counting cells with a Coulter counter

after 24hrs incubation. For each tested compound concentration

triplicate cultures were used. The antiproliferative activity

of the tested compounds was calculated from dose-response

curves and expressed as IC₅₀ (dose causing 50% inhibition cell

growth in treated cultures relative to untreated controls) .

(B) Microtubule assembly-disassembly assay.

Calf brain tubulin was prepared by two cycles of

assembly-disassembly (Shelanski M.L., Gaskin F. and Cantor C.R., Proc.Natl.Acad.Sci. U.S.A. 70, 765-768, 1973) and stored

in liquid nitrogen in MAB (0.1 M MES, 2.5 mM EGTA, 0.5 mM MgS0₄

0.1 mM EDTA, 0.l mM DTT pH 6.4) . All the experiments were

carried out on protein stored for less than 4 weeks. Before

each experiment, the tubulin was kept 30 min at 4°C. Assembly

was monitored by the method of Gaskin et al. (Gaskin F.,

Cantor C.R. and Shelanski M.L., J.Molec.Biol. 89, 737-758, 1974) .

The cuvette (1 cm path) containing tubulin (lmg/ml) and 1

mM GTP was shifted to 37°C and continuous turbidity

measurements were made at 340 nm on a Perkin-Elmer 557 double

wavelength, double beam spectrophotometer equipped with an

automatic recorder and a thermostatically regulated sample

chamber. After 30 minutes, 4 mM CaC12 was added and depolymerisation was measured for 10 minutes as decreased

turbidity. At regular intervals of 15 minutes scaled doses of

the tested compounds were added and variations in the

turbidity were monitored. Data are expressed as percentage of

repolymerization induced by the tested compounds.

The taxane derivatives of formula I and la are thus

antitumour agents. They may also be useful for the preparation of other antitumour agents. A human or animal

suffering from a tumour may thus be treated by a method which

comprises the administration thereto of an effective amount of

a taxane derivative of formula I or la or a pharmaceutically

acceptable salt thereof according to the invention. The condition of the human or animal may thereby be improved.

Examples of tumours that can be treated are sarcomas,

carcinomas, lymphomas, neuroblastomas, melanomas, myelomas, Wilms tumour, leukemias and adenocarcinomas. Taxane

derivatives of formula I or la pharmaceutically acceptable

salts thereof can be used to treat ovarian cancer,

platinum-resistant ovarian cancer, metastatic breast cancer, non-small cell lung cancer, and head and neck cancer. The

invention also provides a pharmaceutical composition which

comprises, as active ingredient, a compound of formula I or la

or a pharmaceutically acceptable salt thereof according to the

invention and a pharmaceutically acceptable carrier or

diluent. The composition of the invention is usually prepared following conventional methods and is administered in a

pharmaceutically suitable form. Administration can be made by

any of the accepted ways for administration of antitumour agents such as intravenous, intramuscular or subcutaneous

injection or topical application. For systemic injection the

active compound may be, e.g., dissolved in a vehicle

consisting of a mixture of polyoxyethylated castor oil

(Chremophor EL) 50% and ethanol 50% and then diluted with

glucose 5% solution at the desired concentration, or in other

pharmaceutically suitable carriers. The amount of the active

compound administered depends on the treated subject, age,

weight, sex etc., and the severity of the affliction. The method of administration depends on the judgement of the

prescribing physician. A suitable dosage for an average 70 kg

person may range from about O.Olg to about lg per day.

The following Examples illustrate the invention but they

are not intended to limit it thereto.

Example 1

(E) -7-0-triethylsilyl-13-deoxy-13-oxymino-baccatin

7-0-triethylsilyloxy-13-keto-baccatin (260mg, 0.37mmol) and

hydroxylamine hydrochloride (130mg, 1.87mmol) were dissolved in

5 pyridine (3mL) and heated to reflux for 12 hours. After

evaporating pyridine under vacuum, the residue was dissolved in

ethyl acetate, washed with 0.5N HCl (x2) , with water, dried over

Na₂S0₄ and concentrated to give a crude product, containing the

(E) -oxime, the (Z)-oxime and some starting ketone. The oximes

10 were separated on silica gel (eluant n-hexane/ethyl acetate

3:1) .

The (E) -oxime was isolated as a white solid (lOOmg, 38% yield) .

TLC (n-hexane/ethyl acetate 1:1) ; Rf=0.54. ^XH NMR (CDC1₃,

400MHz) :0.5-0.7 (m, 6H, Si (CH₂CH₃) ₃) , 0.92

15 (t,J=8.0Hz,9H,Si(CH₂CH₃)₃) , 1.08 (s,3H,17) , 1.23 (s,3H,16), 1.66

(S-3H-19) . 1.75 (S-1H.0H-1) , 1.87 (m, 1H, 6β) , 2.21

(S,3H,COCH₃-10) , 2.22 (s, 3H, C0CH₃-4) , 2.26 (s,3H,18) , 2.54

(m,lH,6α) , 2.78 (d,J= 19.6Hz, 1H, 14-β) , 3.02

(d,J=19.6Hz,lH, 14-α) , 3.80 (d,J=6.7Hz, 1H, 3) ,

204.13 (d,J=8.4Hz,lH,20β) , 4.32 (d,J=8.4Hz, 1H, 20α) , 4.49

(dd,J=6.8, 10.5Hz, lH,H-7) , 4.94 (dd,J=9.4, 1.8Hz, 1H,H-5) , 5.67(d,J=6.7Hz, 1H,2), 6.61 (s-lH-10), 7.4-8.2 (m,5H,phenyl) ,

8.8 (bs,lH,NOH) .

Example 2

(Z) -7-Q-triethyIsilyl-13-deoxy-13-oxymino-baccatin

5 The (Z) -oxime was isolated as a white solid (30mg, 11% yield) ,

(see example 1)

TLC (n-hexane/ethyl acetate 1:1); Rf=0.30. ¹H-NMR(400 MHz,

CDC1₃) :0.60 (m, 6H, Si(CH₂CH₃)₃) , 0.92 (m, 9H,Si (CH₂CH₃)₃) , 1.13

(s,3H,17), 1.21 (s,3H,16), 1.66 (s,3H,19), 1.79 (s,lH,OH-l),

101.90 (m,lH,6β), 2.18 (s,3H,COCH₃-10) , 2.23 (s,3H,COCH₃-4) , 2.43

(s,3H,18), 2.54 (d, J=17.6Hz,lH,14β) , 2.56 (m,lH, 6α) , 3.10 (d,

J=17.6Hz,lH,14α) , 3.76 (d, J=6.4Hz, 1H,3) , 4.17 (d,

J=8.5Hz,lH,20β) , 4.34 (d, J=8.5Hz, 1H, 20α) , 4.54 (dd,

J=6.7Hz,lH,7) , 4.98 (dd, J=1.5, 9.4Hz,lH,5), 5.65 (d,

15 J=6.4Hz,lH,2) , 6.61 (s, 1H,10), 7.4-8.1 (m, 5H,phenyl) .

Example 3

(E) -l3-deoxy-13-oxymino-baccatin

To 7-0-triethylsilyloxy-l3-deoxy-13- (E)oxymino-baccatin (80.4mg,

O.llmmol), dissolved in dry tetrahydrofurane (5mL) , and stirred

20 at 0°C under nitrogen, tetrabutylammonium fluoride (70mL) was

added, the reaction mixture was let to warm up to room temperature and stirred for 14 hours. The mixture was diluted

with ethyl acetate, washed with water, then with brine and dried

over Na₂S0₄. After concentration 62mg (O.lmmol, 90% yield) of

desired compound was obtained. TLC (n-hexane/ethyl acetate 1:1.5); Rf=0.32. ^XH NMR (CDC13,

400MHz) :1.14 (s,6H, 16+17) , 1.66 (s,3H,19), 1.75 (s,1H-OH-1) ,

1.87 (m,lH,6β), 2.14, 2.20, 2.27 (three singlets, 9H, COCH₃-10

+C0CH₃-4+ 18), 2.56 (m,2H, 6α+0H-7) , 2.80 (d,J=19.6Hz, IH, 14-β) ,

3.04 (d,J=19.6Hz,lH, 14-α) , 3.81 (d,J=6.7Hz, IH,H-3) , 4.14

(d,J=8.2Hz,lH,20β) , 4.32 (d,J=8.2Hz,IH,20α) , 4.46 (m,lH,7), 4.97

(dd,J=2.0, 9.7Hz, 1H,5), 5.66 (d,J=6.7Hz, IH,2) , 6.45 (s-lH-10), 7.4-8.2 (m, 5H,phenyl) , 8.0 (bs,lH,NOH).

FAB-MS=m/Z 598 [M-H]

Example 4

(Z) -l3-deoxy-l3-oxymino-baccatin

To 7-0-triethylsilyloxy-13-deoxy-13- (Z) -oxymino-baccatin

(77.3mg, 0.108mmol), dissolved in pyridine (2.5 mL) and stirred at 0°C under nitrogen, 70% HF pyridine complex (0.25 ml) was

added, the reaction mixture was let to warm up to room temperature and stirred for 6 hours. Additional HF pyridine

complex (0.125mL) was added and the mixture stirred at room temperature 2 hours longer. After concentration under vacuum, 66

mg of crude material was obtained. Purification by

chromatography (silica gel, eluant = pet.ether/ethyl acetate

7:8) yielded the desired product, as a white solid (40.7mg, 63% 5 yield) .

TLC (n-hexane/ethyl acetate 1:1.5), Rf=0.22. ^XH-NMR(400MHz,

CDC1₃) :1.13 (s,3H,16), 1.21 (s,3H,17), 1.66 (s,3H,19), 1.89

(m, lH,6β), 2.24, 2.26, 2.32 (three singlets, 9H, COCH₃-4 + COCH₃-

10 +18), 2.59 (m, 3H,OH-7+14β+6α) , 3.10 (d, J=17.6Hz, IH, 14α) ,

103.72 (d, J=6.7Hz,lH,3) , 4.17 (d, J=8.2 Hz,lH,20β), 4.34 (d,

J=8.2Hz,lH,20α) , 4.50 (m,lH,7), 5.02 (dd, J=2.1, 9.6Hz,lH,5),

5.65 (d, J=6.7Hz,lH, 2), 6.44 (S,1H, 10), 7.4-8.1 (m, 5H,

phenyl) .

FAB-MS: m/Z 598 [M-H] 15 Example 5

(E) -13-deoxy-13-0- (S) -N- (tertbutoxycarbonyl) -α-phenylglγcyll -

oxymino baccatin and (E) -13-deoxy-13-0- \ (R) -N- (tertbutoxy-

carbonyl) -α-phenylcrlycy11 -oxymino-baccatin A solution of (E) -13-deoxy-13-oxymino-baccatin (117mg,

200.195mmol) , 1, 3-dicyclohexylcarbodiimide (DCC, lOOmg, 0.48mmol),

(S) -BOC-L-α-phenyl-glycine (lOOmg, 0.4mmol), N,N-dimethyl pyridine (DMAP, cat. amount) in toluene (12mL) was stirred at

room temperature for 7 hours, the reaction mixture was filtered

and concentrated to give a crude product (255mg) that was

purified by chromatography (silica gel, eluant: n-hexane/ethyl

acetate 1.5:1) and then by preparative TLC (eluant: n-

hexane/ethyl acetate 1:1) . Two products were obtained, identical

except for the stereochemistry of the carbon in the side chain:

isomer 1 (24mg, 15%) , isomer 2 (31mg, 19%) .

Isomer l: TLC (n-hexane/ethyl acetate 1:1); Rf=0.34. ^- MR (400

MHz, CDC1₃) : 1.05 (s,3H,17), 1.11 (s,3H,16), 1.45 (s, 9H, t-Bu) ,

1.62 (S.3H.19), 1.78 (bε, IH,OH-l) , 1.84 (m, IH, 6β) , 1.95 (s,

3H,CH₃CO-4), 2.21 (s,3H,l8), 2.27 (s, 3H,CH₃CO-10) , 2.54 (m, 2H,

6α+OH-77, 2.66 (d,J=19.9 Hz,lH,14β), 3.02 (d, J=19.9 Hz,

lH,14α), 3.76 (d, J=6.7 Hz, IH,3) , 4.08 (d, J=8.5Hz, 20β) , 4.31

(d,J=8.5Hz,20α) , 4.44 (dd, J=6.7, 10.5Hz, IH, 7), 4.91

(d,J=8.5Hz,lH,5) , 5.50 (d, J=7.4Hz,lH, NH-3 ' ) , 5.56 (d, J=7.4

Hz,lH, 2'), 5.61 (d, J=6.7Hz,lH,2) , 6.42 (s,lH, 10), 7.2-8.2 (m,

10H, two phenyls) . (FAB-MS=m/z 834 (M+H) Isomer 2= TLC (n-hexane/ethyl acetate 1:1); Rf=0.29. ^-NMR

(400MHz, CDC1₃) : 1.11 (s, 3H, 17), 1.12 (s, 3H.16). 1.25 (s, 3H,

COCH₃-4), 1.42 (s, 9H, t-Bu) , 1.60 (s, 3H, 19), 1.80 (m, IH, 6β) ,

1.85 (S, IH, OH-1) , 2.19 (s, 3H, 18), 2.27 (s, 3H, COCH₃-10),

52.49 (m, 2H, 6α +OH-7) , 2.87 (s, 2H,14), 3.70 (d, d, J=6.7

Hz,lH,3), 4.04 (d, J=8.5 Hz,lH,20β), 4.23 (d,J=8.5 Hz,lH,20α),

4.39 (dd, J=6.7,10.8 Hz.lH-7), 4.83 (dd, J=l.9, 9.5Hz, IH, 5) , 5.48

(d, J=7.0Hz,lH,2' ) , 5.60 (d, J=6.7Hz, IH,2) , 5.65 (d, J=7.0Hz,NH-

3'), 6.40 (s,lH, 10), 7.3-8.1 (m, 10H, two phenyls) . 10 FAB-MS: m/z 834 (M+H)

Example 6

(Z) -13-deoxy-13-Q- \ (S) -N- (tertbutoxycarbonyl) -α-phenylglycyll -

oxymino-baccatin

A solution of (Z) -13-deoxy-13-oxymino-baccatin (37mg, 0.06mmol),

15 DCC (24mg, 0.12mmol), BOC-L-α-phenylglycine (20mg, O.Oδmmol),

DMAP (cat. amount) in toluene (4mL) was stirred at room

temperature for 2.5 hours. The reaction mixture was filtered and

concentrated to give a crude product (76mg) that was purified by chromatography (silica gel, eluant: n-hexane/ethyl acetate

2011:14) to yield the title product as a white solid (30mg, 60%

yield) . TLC (n-hexane/ethyl acetate 1:1); Rf=0.27. ¹H-NMR(400 MHz,

CDC1₃) :1.06 (s,3H,17), 1.10 (S,3H,16), 1.45 (s, 9H, t-Bu), 1.65

(s,3H,19), 1.75 (s-lH-OH-l), 1.88 (m,IH, 6β) , 2.18

(S-3H-18) ,2.20 (s,3H,COCH₃-4) , 2.28 (s,3H,COCH₃-10) , 2.43 (d,

5 J=4.1Hz,lH,OH-7) , 2.57 (m,lH,6α), 2.79 (d,J=18.2 Hz, IH, 14β) ,

3.18 (d,J=18.2 Hz,lH,14α), 3.64 (d,J=6.6Hz, IH,3) , 4.16 (d,J=8.5

Hz,lH,20β), 4.32 (d,J=8.5 Hz,IH,20α) ,4.45 (m,lH,7), 4.97

(dd,J=2.2, 9.5 Hz, IH, 5), 5.50 (m,2H, 2' + NH-3 ' ) , 5.62 (d,J=6.6 Hz-IH.2) . 6.37 (s,lH,10), 7.2-8.1 (m, 10H, two phenyls) .

10 FAB-MS:m/Z 834 (M+H)⁺

Example 7

7-Q-triethylsilyl-13-deoxy-13-imino-baccatin To a solution of 7-O-triethylsilyloxy-13-oxymino-baccatin

(mglOO, 0.14mmol) and 51% hydrazine hydrate (350mL) in ethanol

15 (7mL) , Aldrich W-2 Raney-nickel (lOOmg, as aqueous slurry,

after washing with water and ethanol) was added. The reaction

mixture was stirred at room temperature for 12 hours, then was

filtered through celite and purified by preparative TLC (eluant:

n-hexane/ethyl acetate 1:4) to give the title compound (25mg,

2025% yield) as a white solid. TLC (n-hexane/ethyl acetate 1:4) ; Rf=0.32. ^-N R (400 MHz,

CDC1₃) :0.59 (m, 6H, Si (CH₂CH₃) ₃) , 0.92 (t, J=7.8 Hz, 9H,

Si(CH₂CH₃)₃) , 1.11 (S-3H.17) , 1.25 (s,3H,16) , 1.66 (s,3H,19) ,

1.87 (m,lH,6β) , 2.19, 2.21, 2.28 (three singlets, 9H,CH₃CO-

4+CH₃CO-10 + 18) , 2.52 (m, IH, 6α) , 2.69 (d,J=19Hz, IH, 14b) , 3.10

(d, J=19Hz,lH,14α) , 3.88 (d,J=6.8 Hz,lH,3) , 4,14 (d, J=8.5

Hz,lH,20β), 4.31 (d,J=8.5Hz, IH, 20α) , 4.48 (m, 1H,7), 4.93 (d,

J=9.7 Hz.lH.5) , 5.66 (d, J=6.8Hz, IH,2) , 6.60 (s,lH,10), 7.5-8.1 (m,5H, phenyl)

Example 8

7-Q-triethγlsilyl-10-deacetoxy-13-deoxy-13-imino-baccatin To a solution of 7-0-triethylsilyloxy-13-oxymino-baccatin (50mg,

0.07mmol) and 51% hydrazine hydrate (158mL) in ethanol (3mL) ,

Raney-nickel aqueous slurry (50mg) was added. The reaction mixture was stirred at room temperature for 3 hours, then was

filtered through celite and purified by preparative TLC (eluant:

n-hexane/ethyl acetate 1:4) to give the title compound (40mg,

90% yield) as a white solid.

TLC (n-hexane/ethyl acetate 1:4); Rf=0.22. ¹H-NMR(400 MHz,

CDC1₃) :0.58 (m, 6H,Si (CH₂CH₃)₃) , 0.95 (t, J=7.9 Hz, 9H,Si (CH₂CH₃)₃) ,

1.13 (s,3H-17), 1.19 (s,3H,16), 1.59 (s,3H,19), 1.86 (m,IH, 6β) , 2.07 (d, J=1.2 Hz,3H, 18) , 2.20 (s, 3H,0C0CH₃) , 2.50 (m, IH, 6α) ,

2.68 (d, J=18.7Hz,lH,14β) , 3.09 (d, J=18.7Hz , IH, 14α) , 3.60

(dq, J=14.5,1.2Hz,lH,10β) , 3.93 (d, J=14.5 Hz , IH, 10a) , 4.07

(d, J=6.5Hz,lH,3) , 4.12 (d, J=8.2Hz, IH, 20β) , 4.31 (d,J=8.2

Hz,lH,20α), 4.50 (dd,J=6.7, 10.5Hz, IH, 7) , 4.93 (d,J=7.6Hz, IH, 5) ,

5.64 (d, J=6.5Hz, 1H,2) , 7.4-8.1 (m, 5H, phenyl).

FAB-MS=m/z 640 [M+H]⁺ .

Example 9

10-Peacetoxy-13-deoxy-13-imino-baccatin

To a solution of 7-O-triethylsilyl-10-deacetoxy-13-deoxy-13- imino-baccatin (34mg, 0.053mmol) in THF (4mL) at 0°C, a 1M

solution of tetrabutylammonium fluoride in THF (60μL) was added

and the reaction mixture was stirred for 2 hours at 0°C. The reaction mixture was poured into ice-water and extracted with

ethyl acetate. The organic layer was washed with brine, water, dried over Na₂S0₄ and concentrated under vacuum. The crude

product was purified by silica gel chromatography

(eluant:dichloromethane/methanol 19:1) yielding 24 mg of the

title compound (86%) ,- TLC (dichloromethane/methanol 19:1); Rf=0.27. ^XH-NMR (400 MHz,

CDC1₃) :1.14 (S.3H.17); 1.19 (S,3H, 16); 1.61 (s, 3H,19); 1.78 (m,lH,6β) ; 2.06 (d, J=1.2 Hz,3H,18) ; 2.20 (s, 3H,CH₃CO) ; 2.63

(m, lH,6α) ; 2.69 (dd, J=18.8, 1.1Hz, IH, 14β) ; 3.12 (d, J=18.8

Hz,lH,14α) ; 3.67 (dq, J=14.9,1.2 Hz,lH,10β) ; 4.00 (d, J=14.9

Hz.lH-lOα) ; 4.14 (m, 2H,20β +3) ; 4.36 (m,2H, 20α + 7) ; 4.95 (dd,

J=9.4, 2.1 Hz, IH, 5) ; 5.68 (dd, J=6.8, l.lHz-lH-2) ; 7.4-8.1

(m, 5H,phenyl) .

Example 10

7-0-triethylsilyl-ll-hydro-12.13 ene-13-deoxγ-13-amino-baccatin

A solution of 7-0-triethylsilyloxy-13-deoxy-13-imino-baccatin

(60mg, 0.086mmol) , para-toluensulfonic acid (lOmg) , NaBH₃CN

(60mg) in methanol (lmL) was stirred at room temperature for 30

minutes. The reaction mixture was concentrated, dissolved in

ethyl acetate, the organic layer was washed with brine and

water, dried over Na₂S0₄ and concentrated to give the desired

product (60 mg, quant.) .

TLC (n-hexane/ethyl acetate 2:3) ; Rf=0.45. ¹H-NMR(400MHz, CDC1₃)

:0.54 ( , 6H, Si (CH₂CH₃) ₃) , 0.89 (t, J=7.9 Hz, 9H, Si (CH₂CH₃) ₃) ,

1.08 (s-3H,16) . 1.12 (S-3H.17) , 1.60 (s,3H,19), 1.72 (s,3H,18) ,

1.85 (m,lH, 6β) , 1.93 (m, IH, 14β) , 2.17, 2.33 (two singlets, 6H,

CH₃C0-4+ CH₃CO-10) , 2.41 (s,lH,13), 2.49 (m, IH, 6α) , 2.66

(d,J=17.3Hz,lH,14α) , 4.18 (d,J=5.5Hz, IH, 3) , 4.24 (d,J=8.5Hz,lH,20α) , 4.40 (m,2H,20β + 7), 4.91 (dd,J=2.3,

9.7Hz,lH,5), 5.50 (dd, J=1.8, 5.5Hz,lH,2), 5.95 (S,1H,10), 7.4-

8.1 (m, 5H,phenyl) .

FD-MS=m/Z 699

5 Example 11

7-Q-triethylsilyl-10-deacetoxy-ll-hydro-12,13 ene-13-deoxy-13-

amino-baccatin

A solution of 7-0-triethylsilyloxy-10-deacetoxy-13-deoxy-l3- imino-baccatin (26mg, 0.037mmol), para-toluensulfonic acid 10 (2mg) , NaBH₃CN (mg35) in methanol (2mL) was stirred at room

temperature for 20 minutes. The reaction mixture was concentrated, dissolved in ethyl acetate, the organic layer was

washed with brine and water, dried over Na₂S0₄ and concentrated

to give the desired product (20mg, 84% yield) .

15 TLC (n-hexane/ethyl acetate 2:3); Rf=0.5. ^-NMR (400 MHz, CDC1₃]

:0.52 (m, 6H,Si(CH₂CH₃)₃) , 0.90 (t, J=7.9Hz, 9H,Si(CH₂CH₃)₃) ,

1.10(s,3H,17) , 1.15(s,3H,16) , 1.59 (s,3H,19) , 1.86 (m, IH, 6β) ,

1.89(m,lH,14β) , 2.04 (s,3H,18) , 2.20 (s,3H,OCOCH₃) , 2.43 (s, IH, 13) ,

2.50(m,lH.6α) , 2.69 (d,J=18.7Hz, IH, 14α) , 3.55 (dq, J=14.5,

201.2Hz, lH,10β) , 3.89 (d,J=14.5Hz, IH, 10α) , 4.08 (d,J=6.5Hz, IH,3) ,

4.12(d,J=8.2Hz,lH,20α) , 4.31 (d, J=8.2Hz, IH,20β) , 4.50 (m,IH, 7) , 4.93(d,J=7.6Hz,lH,5) , 5.64 (d,J=6.5Hz, IH,2) , 7.4-8.1(m,

5H,phenyl) .

FD-MS:m/Z 641

Example 12

7-O-triethylsilyl-13-deoxy-13-acetylimino-baccatin To a solution of 7-0-triethylsilyl-13-deoxy-13-imino-baccatin

(lOmg, 0.014mmol) in THF (lmL) at 0°C, acetic anhydride (6μL)

was added. After 30 minutes stirring at 0°C the reaction mixture was poured into cold water and extracted with ethyl acetate.

The organic phase was washed with brine and water, dried over

Na₂S0₄ and concentrated to give the title compound (85% yield) .

TLC (n-hexane/ethyl acetate 1:1); Rf=0.58.

Example 13

7-0-triethylsilyl-10-deacetoxy-13-deoxy-acetylimino-baccatin

To a solution of 7-0-triethylsilyl-10-deacetoxy-13-deoxy-13-

imino-baccatin (200mg, 0.3mmol) in THF (12mL) at 0°C, acetic

anhydride (125μL) was added. After 30 minutes stirring at 0°C

the reaction mixture was poured into cold water and extracted

with ethyl acetate. The organic phase was washed with brine and

water, dried over Na₂S0₄ and concentrated to give the title

compound (80% yield) . TLC (n-hexane/ethyl acetate 1:1) ; Rf=0.6. ^XH-NMR (400MHZ, CDC1₃)

: 0.5-0.7(m,6H,Si(CH₂CH₃)₃) ; 0.95 (m, 9H, Si (CH₂£H₃) ₃) ; 1.16

(S-3H-17) ; 1.19 (S,3H,16) ; 1.60 (s,3H,19) ; 1.86 (m, IH, 6β) ; 2.04

(S,3H,18) ; 2.18(s,3H,COCH₃-4) ; 2.27 (d,J=19.0Hz, IH, 14β) ; 2.40

(s-,3H,NCOCH₃) ; 2.60 (m, IH, 6α) ; 3.22 (d, J=19.0 Hz,lH,14α) ; 3.58

(d, J=14.4Hz,lH, lOβ) ; 3.96 (d,J=14.4Hz, IH, 10α) ; 4.09

(m,2H,3+20β) ; 4.30 (d,J=8.5 Hz, lH,20α) ; 4.53 (dd,J=10.5; 7.0

Hz-lH-7) ; 4.90 (m-lH-5) ; 5.64 (d,J=6.2Hz, IH, 2) ; 7.4-8.1

(m, 5H,phenyl) ,-

The title compound may be in equilibrium with the following

tautomeric form :

7-O-triethylsilyl-10-deacetoxy-13-deoxy-13.14-ene-13-

acetylamino-baccatin

^-NMR (400MHZ, CDC1₃) : 0.5-0.7 (m, 6H, Si (CH₂CH₃) ₃) ; 0.95

(m,9H,Si(CH₂Cϋ₃)₃) ; 1.11 (s,3H,16) ; 1.25 (s,3H,17) ; 1.66

(S,3H,19) ; 1.90 (m, IH, 6β) ; 1.93 (s,3H,18) ; 2.11 (s, 3H,COCH₃-4) ;

2.17 (s,3H,NCOCH₃) ; 2.47 (m, IH, 6θ) ; 3.54 (d,J=14.7Hz, IH, lOβ) ;

3.74 (d, J=14.7Hz,lH,10α) ; 3.86 (d,J=7.OHz, IH, 3) ; 4.21,4.27 (two

doublets,J=8.2Hz,2H, 20) ; 4.39 (dd,J=10.2, 6.7Hz, IH, 7) ; 4.90

(dd,J=9.4, 2.0Hz,lH,5) ; 5.79 (d, J=7.0 Hz,lH,2) ; 6.34 (s,lH,14) ;

6.74 (s,lH,NHCOCH₃) ; 7.4-8.1 (m, 5H,phenyl) ; Example 14

7-0- triethylsilyl-10-deacetoxy-ll-hydro-l2.13 ene-13-deoxy-13-

acetylamino-baccatin 5 To a solution of 7-0-triethylsilyl-10-deacetoxy-13-deoxy-13-

i ino-baccatin (36mg, 0.056mmol) in THF (2.4mL) at room

temperature, acetic anhydride (120μL) and NaBH₃CN (72mg) were

added. After 40 minutes at room temperature, the reaction

mixture was poured into cold water and extracted with ethyl

10 acetate. The organic phase was washed with brine and water,

dried over Na₂S0₄ and concentrated to give a crude product that

was chromatographed on preparative TLC (eluant: n-hexane/ethyl

acetate 3:7) . The title compound was obtained in 56% yield.

TLC (n-hexane/ethyl acetate 1:1); Rf=0.17. ^XH-NMR (600 MHz,

15 CDC1₃) : 0.5-0.7 (m, 6H,Si (CH₂CH₃)₃) ; 0.8-1.0 (m, 9H,Si(CH₂CH₃)₃) ;

1.12 (S-3H-16); 1.21 (s,3H,17); 1.52 (S-IH.OH-I); 1.58

(S.3H.19); 1.73 (s,3H,18); 1.89 (m, IH, 6β) ; 2.10 (s, 3H,CH₃CONH) ;

2.34 (s,3H,CH₃CO-4) ; 2.42 (m, IH, 6α) ; 2.57 (m, 2H, ll+14α) ; 2.83 (d,

J=13.4Hz,lH,10α) ; 2.96 (m, 2H, lθβ+14β) ; 3.78 (d, J=5.2Hz, IH, 3) ;

204.22 (dd, J=7.1, 10.7Hz, IH, 7) ; 4.30, 4.36 (two doublets, J=8.5Hz,2H,20) ; 4.89 (m,lH,5); 4.47 (dd, J=5.2, 1.1HZ,1H,2) ;

6.52 (S,1H,C0NH) ; 7.4-8.1 (m, 5H,phenyl) .

FAB-MS=m/z 683

Example 15

lO-Deacetoxy-ll-hγdro-12.13 ene-13-deoxγ-13-acetylamino-baccatin

To a solution of 7-0-triethylsilyl-10-deacetoxy-13-deoxy-12, 13

ene-13-acetylamino-baccatin (44mg, 0.064mmol) in THF (4mL) at

0°C, IM tetrabutylammonium fluoride solution in THF (2X70μL) was

added in two portions. After 2 hours at 0°C, the reaction

mixture was poured into cold water and extracted with ethyl

acetate. The organic phase was washed with brine and water,

dried over Na₂S0₄ and concentrated to give a crude product that

was chromotographed on preparative TLC (eluant: n-hexane/ethyl

acetate 1:4) . The title compound was obtained in 75% yield. TLC

(n-hexane/ethyl acetate=l:4) ; Rf=0.1. hl-NMR (400 MHz, CDC1₃)

:1.11 (S,3H,16); 1.20 (s,3H,17) ; 1.61 (s,3H,19); 1.72 (s,3H,18) ;

1. 83 (m,lH,6β) ; 2.10 (S, 3H,CH₃C0NH) ; 2.34 (s, 3H,CH₃C0-4) ; 2.55

(m,3H,6α+ll+14α) ; 2.87 (dd,J=13.8Hz,J=2.OHz, IH, 10a) ; 2.97

(d, J=18.2Hz,lH,14β) ; 3.06 (dd, J=13.8, 11.4Hz, IH, lOβ) ; 3.76 (d,

J=5.3Hz,lH,3) ; 4.12 (m,lH,7) ; 4.32, 4.37 (two doublets, J=8.5Hz,2H,20) ; 4.90 (dd,J=9.4, 2.6Hz,lH,5) ; 5.56

(d,J=5.3Hz,lH,2) ; 6.53 (s,lH, CH₃C0NH) ; 7.4-8.1 (m, 5H,phenyl) .

Example 16

7-0-triethylsilyl-10-deacetoxy-13-deoxy-13-oxymino-14 (β) -hvdroxy-

baccatin To a solution of 7-0-triethylsilyl-10-deacetoxy-13-deoxy-13-

imino-baccatin (55mg, 0.086mmol) in dichloromethane (3mL) , 50%

metachloro perbenzoic acid (52mg) was added and the reaction

mixture stirred at room temperature for 1 hour. More

dichloromethane (20mL) was added and the solution was extracted

with sat.solution of sodium hydrogencarbonate (4 x 25mL) and then washed with brine. The crude product was chromatographed on

preparative TLC (eluant=n-hexane/ethyl acetate 1:1). The title

compound was obtained in 25% yield. Also the 13-oximino derivatives, described in Example 1, were isolated.

TLC (n-hexane/ethyl acetate 1:1); Rf=0.55. l-NMR (400 MHz,

CDC1₃) : 0.5-0.7 (m, 6H,Si(CH₂CH₃) ₂) ; 0.95 (m, 9H,Si (CH₂£H₃)₃;1.11

(S.3H-17); 1.21 (s.3H,16); 1.64 (s,3H,19); 1.88 (m, IH, 6β) ; 2.05

(S-3H-18); 2.26 (s, 3H,COCH₃); 2.47 (m, IH, 6α) ; 3.58 (d,

J=15.0Hz,lH,10β) ; 3.89 (d, J=6.7Hz, IH,3) ; 3.92 (d, J=15.0Hz,lH,

10a) ; 3.97 (s, 1H,0H-1) ; 4.27, 4.29 (two doublets, J=8.5Hz,2H,20) ; 4.46 (dd, J=6.7, 10.6Hz,IH, 7) ; 4.77 (d,

J=2.1Hz,lH,OH-14) ; 4.90 (dd,J=1.7, 9.6 Hz,lH,5); 4.98 (d, J=2.1Hz,14); 5.82 (d, J=6.7Hz, IH,2) ; 7.4-8.1 (m, 5H,phenyl) ; 9.3

(bS,lH,N-OH) .

Example 17

l0-Deacetoxy-13-deoxy-l3-acetγlimino-baccatin (first method)

To a solution of I0-deacetoxy-13-deoxy-13-imino-bacca in (20mg,

0.029mmol) in pyridine (0.5mL) at 0°C, acetic anhydride (30μL)

was added under stirring. After 1 hour at 0°C the reaction

mixture was poured into cold brine and was extracted with ethyl

acetate. The organic layer was washed twice with water, dried over Na₂S0₄ and concentrated under vacuum to yield 19.6 mg of the

title product (91% yield) . TLC (hexane/ethyl acetate 1:1); Rf=0.7

Example 18

10-Deacetoxy-13-deoxy-13-acetylimino-baccatin (second method)

and 10-deacetoxy-l3-deoxy-13.14 ene-13-acetylamino-baccatin

To a solution of 7-0-triethylsilyl-10-deacetoxy-13-deoxy-13- acetylimino-baccatin (23mg, 0.031mmol) in THF (4mL) at 0°C, IM

tetrabutylammonium fluoride in THF (70μL) was added. The

reaction mixture was stirred at 0°C for 2 hours,- then it was poured into ice-water and extracted with ethyl acetate. The

organic layer was separated, washed with brine, with water,

dried over Na₂S0₄ and concentrated under vacuum.

The residue was purified by preparative chromatography over

silica gel (eluant: n-hexane/ethyl acetate 1:1) . A mixture of

the title products (keto-enolic equilibrium products) was

obtained (20 mg, 95% yield)

TLC (hexane/ethyl acetate ) ,- Rf=0.12 (I) and Rf=0.7 (la) .

Example 19 7-0-triethylsilyl-10-deacetoxy-ll-hydro-12.13 ene-13-deoxy-13-

benzoylamino-baccatin

To a solution of 7-0-triethylsilyl-10-deacetoxy-13-deoxy-13-

imino-baccatin (21mg, 0.0328mmol) in anhydrous THF (2mL) at 0°C,

under nitrogen, benzoyl chloride (38μL, 0.327mmol) and NaBH₃CN

(41mg) were added. After 1 hour at 0°C, the reaction mixture was

dissolved in ethyl acetate. The organic solution was poured into

ice, the organic phase was washed with brine and dried over

Na₂S0₄ . The crude product was purified by preparative

chromatography over silica gel (eluant n-hexane/ethyl acetate

2:1) to give the title product (16 mg, 65%) . TLC (hexane/ethyl acetate 1:1); Rf 0.41. ^XH-NMR (400 MHz, CDC1₃)

1.16 (S-3H.17); 1.28 (S-3H-16); 1.61 (S,3H,19); 1.84 (s,3H,18);

1.90 (m,lH,6β) ; 2.11 (s, 3H, CH₃C0) ; 2.46 (m, IH, 6α) ; 2.64 (d,

J=11.7Hz, IH, 11) ; 2.70 (d, J=18.5Hz, IH, 14α) ; 2.90 (dd,

J=13.5, 1.2Hz, lH,10α) ; 3.00 (dd, J=13.5, 11.7Hz, IH, lOβ) ; 3.12 (d,

J=18.5Hz,lH,14β) ; 3.90 (d, J=5.3Hz, IH, 3) ; 4.26 (dd, J=7.3,10.5

Hz, IH, 7) ; 4.31, 4.35 (two doublets, J=8.5Hz, 2H, 20) ; 4.90

(m,lH,5) ; 5.50 (dd, J=5.3, 1.4Hz, IH, 2) ; 7.37 (s, IH, PhCONH) ; 7.4- 8.1 (m,10H,two phenyls) . Example 20

7-Q-triethylsilyl-10-deacetoxy-ll-hvdro-l2.13 ene-13-deoxy-13-

isobutanoylamino-baccatin

To a solution of 7-O-triethylsilyl-10-deacetoxy-13-deoxy-13-

imino-baccatin (30mg, 0.047mmol) in anhydrous THF (3mL) at 0°C,

under nitrogen, isobutanoylchloride (40μL) and NaBH₃CN (60mg)

were added. After 50 minutes at 0°C, the reaction mixture was

poured into ice, the organic material was extracted with ethyl

acetate and washed with brine and dried over Na₂S0₄. The crude product was purified by preparative chromatography over silica

gel (eluant=n-hexane/ethyl acetate 7:3), yielding 24 mg of the

title compound (72%) . TLC (n-hexane/ethyl acetate=7:3) ; Rf=0.51.

Example 21

10-Deacetoxy-ll-hydro-12.13 ene-13-deoxy-13-isobutanoylamino-

baccatin

To a solution of 7-0-triethylsilyl-10-deacetoxy-ll-hydro-13-

deoxy-12,13-ene-isobutanoyl-baccatin (24mg, 0.034mmol) in THF

(2mL) , at 0°C under nitrogen, 50μL of IM solution of

tetrabutylammonium fluoride in THF was added. After two hours to

the reaction mixture ethyl acetate was added, the organic

solution was poured into ice, separated, washed with brine,

water and dried over Na₂S0₄. The crude product was puri ied by

preparative TLC (eluant: n-hexane/ethyl acetate 1:3), yielding

14mg (69%) of the title product.

TLC (n-hexane/ethyl acetate 1:4); Rf=0.29. ^XH-NMR (200 MHz, CDC1₃) : 1.06 (s,3H,17) ; 1.17, 1.21 (two d, J=6.8Hz, CH(CH₃1₂1;

1.24 (S,3H,16) ; 1.59 (s,3H,19) ; 1.69 (S-3H.18) ; 1.72 (s,lH,OH-

1) ; 1.7-2.0 (m,2H,6β + OH-7) ; 2.32 (s, 3H, C0CH₃) ; 2.3-2.7

(m,4H, (CH₃)₂CHCO + 11 + 6α + 14) ; 2.8-3.0 (m, 2H, 10α + 14β) ; 3.04

(dd, J=11.2, 13.8 Hz,lH-10β) ; 3.73 (d, J=5.3Hz, IH, 3) ; 4.09

(m, 1H.7) ; 4.29, 4.35 (two d, J=8.6Hz, 2H, 20) ; 4.88 (dd, J=2.5, 9.2 Hz-lH-5); 5.53 (dd, J=5.3, l.OHz-lH-2); 6.51 (s, IH,CONH) ;

7.4-8.1 (m,5H,phenyl) .

Example 22

10-Deacetoxy-ll-hydro-12.13 ene-13-deoxy-13-benzoylamino-

baccatin

The removal of the 7-0-triethylsilyl group was performed as

described in Example 15.

The title compound was obtained in 75% yield.

TLC (n-hexane/ethyl acetate 1:2); Rf=0.24. ^XH- MR (200 MHz, CDC1₃) : 1.11 (s,3H,17); 1.25 (s,3H,16); 1.62 (s,3H,19); 1.75

(S,1H,0H-1); 1.81 (s,3H,18); 1.85 (m, IH, 6β) ; 2.09 (s,3H,CH₃C0-4) ;

2.4-2.8 (m,3H, 6α+ll+14α) ; 2.91 (dd, J=2.5, 13.8Hz, IH, 10a) ; 3.0-

3.2 (m,2H,10β + 14β) ; 3.84 (d, J=5.2Hz, IH, 3) ; 4.15 (m,lH,7) ;

4.27,4.35 (two doublets, J=8.5Hz, 2H, 20) ; 4.89 (dd, J=2.4, 9.2

Hz,lH,5) ; 5.57 (dd, J=1.0, 5.2 Hz,lH,2) ; 7.34 (s,lH,CONH) ; 7.3-

8.1 (m,10H, two phenyls) .

Example 23

7-0-triethylsilyl-10-deacetoxγ-13-deoxy-13-phenylacetylimino-

baccatin To a solution of 7-0-triethylsilyl-10-deacetoxy-13-deoxy-13-

imino-baccatin (20mg, 0.031mmol) and phenylacetic acid (22mg, 0.16mmol) in anhydrous THF (2mL) , 1,3-dicyclohexylcarbodiimide

(36mg, 0.174 mmol) and a few crystals of N,N-

dimethylaminopyridine were added at room temperature, under

nitrogen with stirring. After 40 minutes the reaction mixture

was filtered on celite, the filtrate was concentrated and

purified on preparative TLC (eluant : n-hexane/ethyl acetate

2:1), yielding 20mg (84%) of the title compound.

i-NMR (200 MHz, CDC1₃) : : 0.5-0.7 (m,6H,Si(CH₂CH₃) ₃) ; 0.9

(m,9H,Si(CH₂CH₃)₃) ; 1.15 (s,3H,17); 1.20 (s,3H,16); 1.6

(S.3H.19); 1.9 (m,lH,6β); 2.0 (S-3H-18); 2.1 (d, IH, 14β) ; ); 2.4

(s,3H,CH₃CO-4) ; 2.5 (m, IH, 6α) ; 3.3 (d, IH, 14α) ; 3.55 (d,lH,10β) ;

3.75 (d,2H,CH₂-phenyl) ; 3.9 (d,lH,10α) ; 4.05 (m, 2H, 3+20β) ; 4.25

(d, lH,20α) ; 4.45 (dd,lH,7) ; 4.90 (m, 1H,5) ; 5.6 (d,lH,2) ; 7.2-

8.1 (m,10H, two phenyls) .

Example 24

7-Q-triethγlsilyl-10-deacetoxy-ll-hγdro-12.13 ene-13-deoxy-13-

phenylacetylamino-baccatin

To a solution of 7-O-triethylsilyl-l0-deacetoxy-13-deoxy-l3-

phenylacetylimino-baccatin (20mg, mmol) in anhydrous THF

(2mL) , cooled at 0°C, NaBH₃CN (47mg) and a few crystals of p-

toluensulfonic acid were added under nitrogen, with stirring. After 2 hours brine was added to the reaction mixture and the

organic material was extracted with ethyl acetate. The organic

layer was dried over Na₂S0₄ , filtered and concentrated under

vacuum. The crude product was purified by preparative TLC

5 (eluant: n-hexane/ethyl acetate 1.5:1), yielding 15mg (75%) of

the title product.

Example 25

10-Deacetoxγ-ll-hγdro-12.13 ene-13-deoxy-13-phenylacetylamino- baccatin

10 The removal of the 7-0-triethylsilyl group was performed as

described in Example 15.

The title compound was obtained in 68% yield.

TLC (n-hexane/ethyl acetate 1:2); Rf=0.22. ^XH-NMR (200 MHz, CDC1₃) : 1.07 (s,3H,16); 1.17 (S.3H.17); 1.49 (s,3H,18); 1.57

15 (s,3H,19) ; 1.64 (s,lH,OH-l) ; 1.79 (m, IH, 6β) ; 2.06 (s, 3H, CH₃CO-4) ;

2.3-2.7 (m,3H, 6α+ll+14α) ; 2.7-2.9 (m,2H,10α + 14β) ; 3.01 (dd,

J=11.3,13.7Hz,lH,10β) ; 3.5-3.8 (m, 3H, 3+ Ph£H₂C0) ; 4.04 (dd,

J=6.9, H.lHz,lH,7) ; 4.27,4.32 (two doublets, J=8.5Hz, 2H, 20) ;

4.82 (dd, J=2.5, 9.3HZ,1H,5); 5.51 (dd, J=1.0, 5.3Hz, IH, 2) ;

206.49 (s.lH.CONH); 7.2-8.1 ( , 10H,two phenyls) . Example 26

7-O-triethylsily-10-deacetoxy-ll-hγdro-12.13 ene-13-deoxy-13-

cinnamoylamino-baccatin

To a solution of 7-O-triethylsilyl-10-deacetoxy-13-deoxy-13-

5 imino-baccatin (20mg, 0.031mmol) in anhydrous THF (2mL) at 0°C,

under nitrogen with stirring, cinnamoylchloride (43mg) and

NaBH₃CN (40mg) were added. After 70 minutes at 0°C, the reaction

mixture was poured into ice-water and extracted with ethyl

acetate. The organic solution was washed with brine, dried over

10 Na₂S0₄ and concentrated under vacuum. The crude product was

purified by preparative chromatography over silica gel (eluant :

dichloromethane/ethyl acetate 17:3), yielding 12mg of the title

compound (50%) .

Example 27 1510-Deacetoxy-ll-hγdro-12.13 ene-13-deoxy -13-cinnamoylamino-

baccatin

The removal of the 7-0-triethylsilyl group was performed as

described in Example 15.

The title compound was obtained in 73% yield.

20 TLC (dichloromethane/methanol 19:1); Rf=0.46. ^XH-NMR (200 MHz,

CDC1₃) : 1.13 (s,3H,16); 1.24 (s,3H,17); 1.60 (S,3H,19); 1.78 (S,3H,18); 1.83 (m, IH, 6β) ; 2.29 (s,3H,CH₃C0-4) ; 2.5-2.8 (m,3H,

6α+ll+14α) ; 2.89 (dd,J-=2.1,13.7Hz,IH, 10CC) ; 3.0-3.3

(m,2H,10β+14β) ; 3.81 (d,J=5.1Hz, IH,3) ; 4.12 (m, 1H,7); 4.30, 4.36

(two doublets, J=8.6Hz,2H,20) ; 4.90 (dd, J=2.3, 9.3Hz,IH,5) ; 5.56

5 (d, J=5.1HZ,1H,2) ; 6.51 (d,J=15.5Hz,IH,Ph-CH=£H) ; 6.74

(S,1H,C0 H); 7.69 (d,J=15.5Hz,IH,Ph-CH=CH) ; 7.3-8.1 (m,10H, two

phenyls) .

Example 28 7-0-Triethγlsilyl-10-deacetoxγ-13-deoxγ -13- ( (4S.5R) -N-benzoyl-

102.2-dimethyl-4-phenyl oxazolidin-5-yl) -carbonylimino-baccatin

To a solution of 7-O-triethylsilyl-10-deacetoxy-13-deoxy-13-

imino-baccatin (50mg, 0.078mmol) and (4S,5R) -N-benzoyl-2,2- dimethyl-4-phenyl oxazolidin-5-carboxylic acid (35mg,

0.107mmol), in toluene (7mL) , N,N-dicyclohexylcarbodiimide

15 (30mg, 0.145mmol) and 4-dime hylaminopyridine (7.5mg, 0.061mmol)

were added and the reaction mixture was stirred under nitrogen

at room temperature for 30 minutes. The reaction mixture was

filtered, the solvent evaporated under vacuum and the crude

product was purified by preparative chromatography over silica

20 gel (eluant : n-hexane/ethyl acetate 2:1), yielding 57mg of the

title compound (76%) . TLC (n-hexane/ethyl acetate 1:1); Rf 0.58. ^-NMR (600 MHz,

CDC1₃) :0.4-0.7 (n.,6H,Si(C_H₂CH₃)₃) ; 0.81,1.11 (two S,6H,16+17) ;

0.94 (m,9H,Si(CH₂Cu₃)₃) ;1.58 (s,3H,19); 1.85 (m,IH, 6β) ;

1.91,1.93,1.93 (three s,9H,18+2 CH₃-5')_; 2.35 (d,

5 J=19.0Hz,lH,14β) ; 2.41 (s, 3H,COCH₃-4) ; 2.47 (m, lH,6α); 3.23 (d,

J=19.0Hz,lH,14α) ; 3.52 (d, J=14.5Hz, IH,lOβ) ; 3.88 (d,

J=14.5Hz,lH,10α) ; 4.02 (d, J=6.6Hz, IH,3) ; 4.07

(d,J=8.5Hz,lH,20β) ; 4.29 (d,J=8.5Hz,IH,20α) ; 4.48

(dd,J=6.8,10.5Hz,lH,7) ; 4.58, 5.22 (two d, J=8.1Hz, 2H, 2'+3' ) ;

104.87 (d,J=8.5Hz,1H,5) ; 5.60 (d, J=6.6Hz, IH,2) ; 6.8-8.1

(m,i5H,three phenyls) . Example 29

lO-Deacetoxy-13.14 ene-13-deoxy -13- ( (4S.5R) -N-benzoyl-2.2-

dimethγl-4-phenyl oxazolidin-5-yl) -carbonyla ino-baccatin

157-0-Triethylsilyl-10-deacetoxy-13-deoxy -13- ( (4S,5R) -N-benzoyl-

2,2-dimethyl-4-phenyl oxazolidin-5-yl) -carbonylimino-baccatin

(20mg, 0.021πτmol) was dissolved in a mixture of ethanol (lmL) ,

0.1N HCl (lmL) and THF (0.5mL) and stirred for 20 hours at room

temperature.

20 The solvent was evaporated under vacuum, water and ethyl acetate

were added, the organic phase was separated and washed with water, dried over Na₂S0₄ and concentrated. The crude product was

purified by preparative chromatography over silica gel (eluant :

n-hexane/ethyl acetate 3:7), yielding lOmg of the title compound

(50%) .

5 TLC (n-hexane/ethyl acetate 1:5); Rf 0.56. ^-NMR (200 MHz,

CDC1₃) : 1.12, 1.33 (two S,6H,16+17); 1.65 (s,3H,19); 1.78

(m,2H,6β+OH-l) ; 1.90, 1.97, 2.00, 2.01 (four s,12H,2 CH₃-5' + 18+

CH₃CO-4) ; 2.59 (m, IH, 6α) ; 3.60 (d,J=15.5Hz,IH,lOβ) ; 3.84 (d,

J=15.5Hz,lH,10α) ; 3.94 (d,J=7.OHz,IH,3) ; 4.1-4.3 (m,3H,7+20);

104.55, 5.19 (two d, J=6.5Hz,2H,2'+3') ; 4.89 (m, 1H,5); 5.82 (d,

J=7.0Hz,lH,2) ; 6.35 (s,lH,14); 6.9-8.1 (m,15H,three phenyls) ;

8.20 (S,1H, H-13) .

Example 30

7-Q-Triethylsilyl-10-deacetoxy-ll-hydro-12.13 ene-13-deoxy -13-

15 ( (4S.5R) -N-benzoyl-2.2-dimethyl-4-phenyl oxazolidin-5-yl) -

carbonylamino-bacca in

To a solution of 7-0-triethylsilyl-10-deacetoxy-13-deoxy -13-

( (4S,5R) -N-benzoyl-2,2-dimethyl-4-phenyl oxazolidin-5-yl) -

carbonylimino-baccatin (50mg, 0.052mmol) in anhydrous THF (6mL) ,

20 cooled to 0°C, under nitrogen, sodium cyano orohydride

(73mg, 1.16mmol) and p-toluensulfonic acid (21mg, 0.12τπmol) were added. The reaction mixture was stirred for 50 minutes, brine

and ethyl acetate were added and the organic phase was washed

with brine, dried over Na₂S0₄, concentrated under vacuum and

filtered through a short pad of silica gel to yield 48mg of the

title compound (96%) .

TLC (n-hexane/ethyl acetate 1:1); Rf 0.5. ^-N R (600 MHz,

CDC1₃) :0.4-0.7 (m,6H,Si(£H₂CH₃)₃) ; 0.93 (m, 9H,Si (CH₂£H₃)₃) ; 1.13,

1.23 (two S,6H,16+17); 1.47 (S,1H,0H-1); 1.58 (s,3H,19); 1.83

(S,1H,18); 1.90 (m, IH, 6β) ; 2.01,2.02 (two s, 6H,2 CH₃-5'); 2.29

(s,3H,C0CH₃-4) ; 2.45 (m,IH, 6α) ; 2.58 (d, J=18.5Hz, IH, 14α) ; 2.65

(d,J=12.2Hz,lH,ll) ; 2.87 (d, J=18.5Hz,IH, 14β) ; 2.90 (d,

J=13.7Hz,lH,10α) ; 2.98 (dd, J=13.7,12.2Hz,IH, lOβ) ; 3.84 (d,

J=5.1Hz,lH,3) ; 4.2-4.4 (m,3H, 7+20); 4.55, 5.24 (two d,

J=6.8Hz,2H, 2'+3'); 4.87 (m-lH-5); 5.46 (d, J=5.1Hz, IH,2) ; 7.76

(s,lH_f H-13) ; 6.9-8.1 ( ,15H,three phenyls) .

Example 31

10-Deacetoxγ-ll-hydro-12.13 ene-13-deoxy -13- ( (4S.5R) -N-benzoγl-

2.2-dimethyl-4-phenyl oxazolidin-5-yl) -carbonylamino-baccatin

7-0-Triethylsilyl-10-deacetoxy-ll-hydro-12, 13 ene-13-deoxy -13-

( (4S,5R) -N-benzoyl-2,2-dimethyl-4-phenyl oxazolidin-5-yl) -

carbonylamino-baccatin (14mg, 0.014mmol) was dissolved in anhydrous ethanol (2mL) containing 2N HCl (lOOmL) . The reaction

mixture was stirred for 2.5 hours at 40°C. The solvent was

evaporated under vacuum, brine and ethyl acetate were added,

the organic phase was dried over Na₂S0₄ and concentrated under

5 vacuum. The residue was purified by preparative TLC (eluant

ethyl acetate/n-hexane 2:1) to yield 8mg of the title compound (68%) .

TLC (n-hexane/ethyl acetate 1:5); Rf 0.54. l-NMR (600 MHz,

CDC1₃) : 1.13, 1.24 (two S,6H,16+17); 1.53 (S,1H,0H-1);

101.6KS-3H.19) ; 1.83 (m,4H, 18+6β) ; 1.99,2.02 (two S, 6H,2 CH₃-5');

2.29 (s,3H,C0CH₃-4) ; 2.56 (m, IH, 6α) ; 2.60 (d, J=18.6Hz, IH, 14α) ;

2.65 (d,J=11.6Hz,lH,ll) ; 2.89 (d, J=18.6Hz, IH, 14β) ; 2.94 (dd,

J=13.9, 1.7Hz, lH,10α) ; 3.10 (dd, J=13.9, 11.6Hz, IH, lOβ) ; 3.84 (d,

J=5.1Hz,lH,3) ; 4.16 (dd,J=7.8, 10.7Hz, IH, 7) ; 4.30, 4.34 (two

15 d,J=8.5Hz,2H,20) ; 4.54, 5.22 (two d, J=6.6Hz,2H, 2' +3' ) ; 4.89

(dd,J=9.2,2.3Hz,lH,5) ; 5.54 (dd, J=5.1, 1.1Hz, IH, 2) ; 7.77

(s-lH.NH-13) ; 6.9-8.1 (m, 15H, three phenyls) .

Claims

1. A taxane derivative of formula I

wherein

R represents a hydrogen atom or a hydroxy group, or taken

together with R₃, a bond,- R_a and R_c are hydrogens and R_b is

hydroxy, or R_a and R_b taken together form a bond and R_c is hydrogen, or R_a is hydrogen atom and R_b and R_c taken together

form a bond, or R_b is azido or amino group and R_c is hydrogen atom;

Ri represents a hydrogen atom, a hydroxy group or a residue

of formula -0C0R' , -OR', -0S0₂R' , -OCONR'R", -0C0NHR' or -0C00R'

wherein R' and R" are each independently C_ι-C₆ alkyl, phenyl-C₂-C₆

alkenyl, or phenyl-C₂-C₆-alkyl, C₃-C₆ cycloalkyl, C₂-C₆ alkynyl or

a phenyl group, optionally substituted with one, two or three

substituents which may be the same or different and which are selected from a halogen atom and C_ι-C₆ alkyl, Ci-C_β alkoxy and

-CF₃ groups; and either

(i) R₂ and R₃ together represent a group of the formula A-N=,

as pure E or pure Z isomers or as a mixture of both E and Z

isomers, wherein A represents:

- a hydrogen atom or a hydroxy, methoxy, acetoxy, amino,

methylamino or dimethylamino group, or

- a group of the formula Y-NH- wherein Y represents either

(a) residue of an amino acid, optionally protected at the

amino group as a N-benzoyl derivative or as a carbamate, or

(b) a chain of the formula II:

wherein:

R₄ is a Ci-Cg alkyl, C₂-C₆ alkenyl, C₃-C₆ cycloalkyl group or a

phenyl or heteroaryl group, optionally substituted with one, two

or three substituents which may be the same or different and

which are selected from a halogen atom and C_ι-C₆ alkyl, Ci-C₆

alkoxy, or -CF₃ groups,- and - 55 - R₅ is -C00R' ' ' or -COR' ' ' or -CONHR' ' ' , wherein R' ' ' is Cι-C₆

alkyl, C₂-C₆ alkenyl, C₃-C₆ cycloalkyl, C₂-C₆ alkynyl or a phenyl

group, optionally substituted with one, two or three

substituents which may be the same or different and which are

selected from a halogen atom and Cι-C₆ alkyl, Cι-C₆ alkoxy and

-CF₃ groups,- or

a group of the formula Y or Y-0- wherein Y is as defined

above,-

a group of the formula COR' wherein R' is as defined above;

or

(ii) R₂ represents a group of the formula B-NH- wherein B

represents

a) hydrogen atom,

b) hydroxy group,

c) amino group,

d) a group of the formula Y-(NH)_n- wherein Y is as defined above

and n is 0 or l, or

e) a group of the formula Y-O- wherein Y is as defined above,-

f) a group of the formula COR', wherein R' is as defined above,-

and R₃ represents hydrogen,-

and pharmaceutically acceptable salts thereof.

2. A compound according to claim 1 wherein:

R_a and R_c are hydrogen atoms and R_b is a hydroxy group.

Ri represents a hydrogen atom, a β-hydroxy group or a residue of

formula -OCOR' , -OR*, -0S0₂R' , -OCONR'R", -OCONHR' or -OCOOR'

wherein R' and R" are each independently Ci-C₄ alkyl, C₂-C₅

alkenyl, C₃-C₆ cycloalkyl, C₂-C₅ alkynyl or a phenyl group,

optionally substituted with one, two or three substituents which

may be the same or different and which are selected from a

halogen atom and Cι-C₄ alkyl, Cι-C₄ alkoxy or -CF₃ groups,- and either:

(i) R₂ and R₃ together represent a group of the formula A-N=, as

pure E or pure Z isomers or as a mixture of both E and Z

isomers, wherein A represents:

- a hydrogen atom, hydroxy, methoxy, acetoxy, amino,

methylamino or dimethylamino groups, or

- a group of the formula Y-NH- wherein Y represents either

(a) residue of an amino acid optionally protected at the

amino group as a N-benzoyl derivative or as a carbamate, or

(b) a chain of the formula II:

wherein :

R₄ is a Ci-C₄ alkyl, C₂-C₅ alkenyl, C₃-C₆ cycloalkyl group or a

phenyl or heteroaryl group, optionally substituted with one, two or three substituents which may be the same or different and

which are selected from a halogen atom and C_ι~C₄ alkyl, C_ι-C₄

alkoxy and -CF₃ groups,-

R₅ is -COOR' ^■ ' or -COR¹ ' ' or CONHR' ' ' wherein R' ' ' is C_ι-C₄

alkyl, C₂-C₅ alkenyl, C₃-C₆ cycloalkyl, C₂-C₄ alkynyl or a phenyl

group, optionally substituted with one, two or three

substituents which may be the same or different and which are

selected from a halogen atom and C_x-C₄ alkyl, Ci-C₄ alkoxy and

-CF₃ groups; or

a group of the formula Y or Y-O- wherein Y is as defined

above,-

or

(ii) R₂ represents a group of the formula -NH-B wherein B

represents

a) hydrogen atom, b) hydroxy group,

c) amino group,

d) a group of the formula Y-(NH)_n- wherein Y is as defined above

and n is 0 or 1, or

e) a group of the formula Y-0- wherein Y is as defined above,

and R₃ represents hydrogen.

3. A compound according to claim 1 or 2 wherein Y represents a

chain of the formula II as defined in claim 1 or a residue of an

amino acid selected from glycine, phenylglycine, serine, 3-

phenylserine and β-alanine.

4. A compound according to any one of the preceding claims

wherein R_λ is OCOCH₃ or a hydrogen atom.

5. A compound according to any one of the preceding claims

wherein B represents hydrogen or a group of the formula Y- where

Y is as defined in claim 1.

6. A compound according to claim 1 which is selected from 13-aza paclitaxel, 13-aza-10-desacetoxy paclitaxel, 13-aza-taxotere, 13-aza-10-deoxy taxotere, 13-aza-10 desacetyl paclitaxel 13-aza-paclitaxel, 13-aza-lO-desacetoxy paclitaxel, 13-aza-lO- desacetyl paclitaxel, 13-aza-taxotere, 13-aza-10-deoxy-taxotere, 10 deacetoxy-13-deoxy-13-imino paclitaxel, 10,13 dideoxy-13- imino taxotere, 13-deoxy-13-imino paclitaxel, 13-deoxy-13-imino taxotere, 10-deacetoxy-13-deoxy-13,14 ene-13-aza-paclitaxel, 13- deoxy-13, 14 ene-13-aza-paclitaxel, 10,13-dideoxy-13, 14 ene-13 aza-taxotere, 13,14 ene-13-aza-taxotere.

7. A process for preparing a taxane derivative of formula I as

defined in claim l, or a pharmaceutically acceptable salt

thereof which process comprises: (a) reacting a 7-protected-13-

keto-baccatin derivative of formula III

III

wherein R_x R. and R_c are as defined in claim l and R'_b is either R_b except for NH₂ or OH or a protected amino or hydroxy group, with

hydroxylamine, O-methylhydroxylamine, methylhydrazine, N,N-

dimethylhydrazine or with ammonia or an ammonium salt and

optionally acylating the resulting compound thereby to give a

compound of formula IV, IVb, Ivd, IVd, V or VI:

IVd IV d

PhCOO OCOCH-

V VI

wherein R' is as defined in claim 1, R_a, R'_b, R_c,and R-. are as

above defined, A_x represents methoxy or acetoxy and A₂ represents

a methylamino or dimethylamino group (b) optionally reacting the resultant 13-hydrazone of formula

VI with anhydrous hydrazine (H₂N-NH₂) to give a taxane derivative of formula VII

wherein R_a, R'_b, R_c and R_x as above defined, which is then

optionally reduced to a hydrazine derivative of formula VIII:

wherein R_a, R'_b , R_c and R₁ are as above defined; (c) optionally partially reducing the said 13-oxime derivative

of formula IV to give the 13-hydroxylamine derivative of formula

IVa or the 13-imino derivative of formula IVb as defined above:

(C) optionally oxidizing a derivative of formula IVb as

above defined to give a derivative of formula IVc,

wherein R_1; R_a, R'_b, and R_c are as defined above,-

(d) optionally reducing the 13-derivative of formula IV, IVa, IVc, V or VI to give the 13-amino derivative of formula IX:

wherein R , R_a, R'_b and R_c are as above defined and R is H or OH; (e) optionally acylating the C-13 derivative of formula IV, IVa,

Ivb VII, VIII or IX with a protected amino acid or with a

compound of formula Xa, Xb, Xc or Xd optionally conveniently

activated at the carboxy group:

Xa Xb Xc Xd

wherein R_A is a hydroxy protecting group and R_B is H or CH₃, R_c is

CH₃ or an optionally substituted phenyl group, R_D is an

optionally substituted phenyl group, R₄ and R₅ are as defined in

claim 1, in the presence of a condensing agent to give a

protected intermediate of the formula XI :

wherein R, R_a, R'_b, R_c are as above defined, and R₂ and R₃ are

as defined in claim 1 or a protected precursor thereof, (f) deprotecting or reducing when necessary the resultant said

compound of the formula IV, IVa, IVb, IVc, IVd, V, VI,

VII, VIII, IX or XI to give the said taxane derivative of the

formula I; and

(g) optionally salifying the said taxane derivative of the

formula (I) to give a pharmaceutically acceptable salt thereof

8. A process according to claim 7, wherein the protected

intermediate of formula XI is:

,

Y-

wherein Y is as defined in claim 1 and R₆ is a hydroxy

protecting group.

9. A compound of the formula IV, IVa, IVb, IVc, IVd, V, VI, VII,

VIII, IX or XI as defined in claim 7.

10. A compound of formula la

wherein R_x R_a, R_b and R_c are as defined in claim 1 and R₇

represents a hydrogen atom or an acyl residue of formula COR' or

Y wherein Y and R' are defined in claim 1 and pharmaceutically

acceptable salts thereof.

11. A process for preparing a compound of formula la, as

defined in claim 9 or a pharmaceutically acceptable salt

thereof, which process comprises: (a) reducing a compound of the formula IVb as defined in

claim 7, optionally in the presence of an acylating agent, to

give a compound of formula XII

wherein R_a, R'_b, R_c, R_x are as defined in claim 7 and R₇ is

as defined in claim 9 except that R₇ is not a hydrogen atom,-

(b) deprotecting the compound of formula XII to give a said

5 compound of the formula la,- and

(c) optionally salifying the thus obtained compounnd of formula

la to give a pharmaceutically acceptable salt thereof.

12. A compound according to claim 10 which is selected from 10-

deacetoxy-ll hydro-Δ^12,13 -13-deoxy-13-aza paclitaxel,

10 10-deacetoxy-hydro-Δ¹²'¹³ -13-deoxy-13-aza taxotere,

11-hydro-Δ¹²'¹³ -13-deoxy-13-aza paclitaxel, 11-hydro-Δ^12,13 -13-

deoxy-13-aza taxotere.

13. A pharmaceutical composition which comprises a compound

of the formula I or la as defined in any one of claims 1 to 6, 9

15 and 10 or a pharmaceutically acceptable salt thereof together

with a pharmaceutically acceptable diluent or carrier.

14. A taxane derivative of the formula I or la as defined

in any one of claims 1 to 6 or 9 or a pharmaceutically

acceptable salt thereof for use as an antitumour agent.

15 A compound according to claim 1 or 10 which is

wherein Rι , R₄ and R₅ are as def ined in claim 1

16. A compound according to claim l or 10 which is

wherein Rι,R₄ and R₅ are as defined in claim 1

17. A compound according to claim 1 or 10 which

wherein R_ι,R₄ and R₅ are as defined in claim 1.

18. A compound according to claim 1 or 10 which is

wherein Rι,R₄ and R₅ are as defined in claim 1.